Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme a reductase

CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species

1986 • 376 citations

Expanded Clinical Evaluation of Lovastatin (EXCEL) Study Results

1991 • 343 citations

Metabolic disposition studies on simvastatin, a cholesterol-lowering prodrug.

1990 • 240 citations

The Effect of Hepatic Enzyme-Inducing Drugs on Thyroid Hormones and the Thyroid Gland*

1991 • 222 citations

Preclinical evaluation of lovastatin

1988 • 203 citations

Disposition of pravastatin sodium, a tissue‐selective HMG‐CoA reductase inhibitor, in healthy subjects.

1990 • 174 citations

Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo

1989 • 172 citations

Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers

1992 • 170 citations

Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia

1993 • 166 citations

ANTICONVULSANT DRUGS AND CANCER A Cohort Study in Patients with Severe Epilepsy

1979 • 160 citations

In vitro and in vivo biotransformation of simvastatin, an inhibitor of HMG CoA reductase.

1990 • 152 citations

Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin

1990 • 149 citations

The physiological disposition of lovastatin.

1989 • 123 citations

Enhancement of Spontaneous Hepatic Tumorigenesis in C3H Mice by Dietary Phenobarbital2

1973 • 122 citations

The Lovastatin-Treated Rodent: A New Model of Barrier Disruption and Epidermal Hyperplasia

1991 • 116 citations

Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin

1991 • 110 citations

Biotransformation of pravastatin sodium in humans.

1991 • 108 citations

HMG‐CoA Reductase Inhibitors: An Exciting Development in the Treatment of Hyperlipoproteinemia

1991 • 105 citations

Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans

1992 • 103 citations

Toxicity of the HMG-coenzyme A reductase inhibitor, lovastatin, to rabbits.

1989 • 95 citations

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia

1990 • 82 citations

Pharmacokinetics of Fluvastatin and Specific Drug Interactions

1993 • 82 citations

Biotransformation of fluvastatin sodium in humans.

1993 • 81 citations

Clinical experience with lovastatin

1990 • 79 citations

Effects of lovastatin and pravastatin on sleep efficiency and sleep stages

1991 • 71 citations

Physiological Disposition of Hmg-Coa-Reductase Inhibitors

1990 • 68 citations

Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance

1992 • 68 citations

A multicenter comparative trial of lovastatin and pravastatin in the treatment of hypercholesterolemia

1993 • 55 citations

The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia.

1993 • 54 citations

Single‐Dose Pharmacokinetics of Pravastatin and Metabolites in Patients with Renal Impairment

1992 • 52 citations

Generalized Eczematous Skin Rash Possibly due to HMG-CoA Reductase Inhibitors

1993 • 51 citations

Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants.

1992 • 44 citations

Pharmacokinetic interaction between propranolol and the HMG‐CoA reductase inhibitors pravastatin and lovastatin.

1991 • 43 citations

Studies on the Mechanism of Simvastatin-Induced Thyroid Hypertrophy and Follicular Cell Adenoma in the Rat

1991 • 42 citations

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase.

1991 • 40 citations

Continuous Infusion of Lidocaine in Patients With Cardiac Arrhythmias

1981 • 36 citations

Epignetic effects of liver tumor promoters and implications for health effects

1983 • 35 citations

Biotransformation of lovastatin. II. In vitro metabolism by rat and mouse liver microsomes and involvement of cytochrome P-450 in dehydrogenation of lovastatin.

1990 • 30 citations

Clinical pharmacology of pravastatin, a selective inhibitor of HMG-CoA reductase

1991 • 23 citations

Myopathy associated with HMG-CoA reductase inhibitors (HMGRIs) and cydosposin A: evaluation in a rat model

1992 • 19 citations

Epigenetic Effects of Liver Tumor Promoters and Implications for Health Effects

1983 • 15 citations

Cited By (0)

Loading...